TRPV4 mediates the reorientation of endothelial cells to integrin signaling, which is the first step of neoangiogenesis [52]; however, the expression of TRPV4 was suppressed in tumor endothelial cells resulting in abnormal angiogenesis via increased Rho activity, and the combination therapy of Rho kinase inhibitor and anti-cancer drug can significantly reduce tumor growth [53]. Here, TRPV4 is linked to neoplasm.